NCT06001788 2025-12-03Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1 Recruiting171 enrolled
NCT03578367 2025-11-10Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)NovartisPhase 2 Completed104 enrolled 11 charts
NCT04260022 2025-11-05Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLAscentage Pharma Group Inc.Phase 1 Recruiting242 enrolled
NCT06501196 2025-09-24A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeBlossomHill TherapeuticsPhase 1 Recruiting170 enrolled
NCT07157514 2025-09-10Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLActinium PharmaceuticalsPhase 2/3 Not yet recruiting306 enrolled
NCT04789655 2025-05-31Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid LeukemiaCelgenePhase 1 Terminated45 enrolled
NCT03066648 2025-05-18Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSNovartisPhase 1 Completed241 enrolled